Clinical trial · Interventional

HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma

An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients With Refractory or Relapsed Non-Cutaneous CD4+ T-Cell Lymphoma

NCT00877656CI-TRIAL-00075117completedPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

The purpose of this study is to assess the safety and efficacy of treatment of non-cutaneous T-cell lymphoma with treatment with CD4.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
T Cell Lymphoma	T-Cell Non-Hodgkin Lymphoma	ALIAS	0.90

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
HuMax-CD4	Biological	—	UNRESOLVED

Design

Arms and outcomes

Arms (1)

type
EXPERIMENTAL
label
CD4
description
Open label treatment arm
interventionNames
1. Biological: HuMax-CD4

Primary outcomes (1)

measure
Efficacy as measured by survival and time to disease progression
timeFrame
12 months

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years

Show eligibility criteria text

Inclusion Criteria:

* Diagnostic biopsy of non cutaneous T Cell lymphoma with positive phenotype
* Relapsed or refractory to minimum of one course of chemotherapy
* Study is closed to enrollment.

References

Publications (1)

BACKGROUNDd'Amore F, Radford J, Relander T, Jerkeman M, Tilly H, Osterborg A, Morschhauser F, Gramatzki M, Dreyling M, Bang B, Hagberg H. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br J Haematol. 2010 Sep;150(5):565-73. doi: 10.1111/j.1365-2141.2010.08298.x. Epub 2010 Jul 14. PMID 20629661